Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Composite Lymphoma 1Breast Neoplasms 1

Interventions

Rituximab 14Cyclophosphamide 10Magnetic Resonance Spectroscopy 8Lenalidomide 8venetoclax 6Specimen Handling 6obinutuzumab 5ibrutinib 5Prednisone 5Biopsy 5zanubrutinib 4fludarabine phosphate 4fludarabine 4Whole-Body Irradiation 4Vincristine 4CT-P10 4polatuzumab vedotin 3orelabrutinib 3Mycophenolic Acid 3Doxorubicin 3Cyclosporine 3Bendamustine Hydrochloride 3pirtobrutinib 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Busulfan 2voruciclib 1treosulfan 1tafasitamab 1prednylidene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, B-Cell, Marginal Zone × ALX148 × 90 days × Clear all
NCT05025800 2026-03-20

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Composite Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡